Source:http://linkedlifedata.com/resource/pubmed/id/17456720
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2007-8-6
|
| pubmed:abstractText |
Derivative chromosome 9 deletions are seen in 10% to 15% of patients with chronic myelogenous leukemia and have been associated with a poor prognosis; however, no studies have been performed in the context of a randomized clinical trial. We developed a DNA-based deletion screen and investigated 339 chronic phase patients treated with interferon-alpha as first-line therapy in 3 controlled German studies with a median observation time of 7 years. Deletions were detected in pretreatment DNA of 59 of 339 (17%) patients. Of these, 21 spanned the ABL/BCR junction and 38 were centromeric (n = 20) or telomeric (n = 18) of the breakpoint. There was no significant difference in overall survival between deleted and nondeleted patients. Patients with breakpoint-spanning deletions had poorer survival compared with patients without deletions (4.7 versus 7.8 years; P = .003), but this was not significant when censored at allogeneic stem cell transplantation (n = 129) or imatinib (n = 62) treatment in the first chronic phase (P = .078). Unexpectedly, deletions that did not span the breakpoint were associated with improved survival compared with cases without deletions (P = .001). Multiple Cox regression analysis indicated that deletion status (P = .007), age (P = .018), and spleen enlargement (P < .001) were significant independent indicators of survival and confirmed that only deletions spanning the ABL/BCR breakpoint were associated with an adverse prognosis (P = .039).
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/BCR protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Fusion Proteins, bcr-abl,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcr,
http://linkedlifedata.com/resource/pubmed/chemical/abl-bcr fusion protein, human
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:ChaseAndrewA,
pubmed-author:CrossNicholas C PNC,
pubmed-author:German Chronic Myelogenous Leukemia (CML) Study Group,
pubmed-author:HaferlachClaudiaC,
pubmed-author:HehlmannRüdigerR,
pubmed-author:HochhausAndreasA,
pubmed-author:KreilSebastianS,
pubmed-author:PfirrmannMarkusM,
pubmed-author:ReiterAndreasA,
pubmed-author:WaghornKatherineK
|
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
110
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1283-90
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:17456720-Adolescent,
pubmed-meshheading:17456720-Adult,
pubmed-meshheading:17456720-Aged,
pubmed-meshheading:17456720-Aged, 80 and over,
pubmed-meshheading:17456720-Blast Crisis,
pubmed-meshheading:17456720-Child,
pubmed-meshheading:17456720-Chromosome Deletion,
pubmed-meshheading:17456720-Chromosomes, Human, Pair 9,
pubmed-meshheading:17456720-Disease Progression,
pubmed-meshheading:17456720-Female,
pubmed-meshheading:17456720-Fusion Proteins, bcr-abl,
pubmed-meshheading:17456720-Genes, abl,
pubmed-meshheading:17456720-Humans,
pubmed-meshheading:17456720-Karyotyping,
pubmed-meshheading:17456720-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:17456720-Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative,
pubmed-meshheading:17456720-Male,
pubmed-meshheading:17456720-Middle Aged,
pubmed-meshheading:17456720-Prognosis,
pubmed-meshheading:17456720-Proto-Oncogene Proteins c-bcr,
pubmed-meshheading:17456720-Survival Rate
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia.
|
| pubmed:affiliation |
Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, United Kingdom.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|